THE ONE THING
Proven Healthcare funds quietly exit BSX and LLY as headlines turn warm
By Cathy · Lead Analyst, Fundprints
Big-name commentary on Eli Lilly, the pharmaceutical giant behind some of the world's best-selling diabetes and weight-loss drugs, kept the bulls loud this week. Meanwhile Boston Scientific, whose devices guide catheters through hearts and nerves in operating rooms worldwide, dropped 6% after a cyberattack forced it to cut its full-year earnings forecast…
The historical echo (what happened the last time this setup appeared) is in the full memo.
THE STORYLINES
Healthcare's two loudest names reach late stage as evidence cools
2 names · Healthcare · names in the full memo
ALSO IN THIS EDITION
- What's not happening: the silences and price-vs-evidence divergences nobody else tracks
- The tape: all 3 Prints this week, each with its base rate and why it matters
- For your book: what this week's evidence changes for the names you hold
Read the full memo.
The storylines in full, the historical echo, every Print with its base rate, and what it means for the names you actually own. New edition every week.